We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
-14.15%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$5.67B
AUM Growth
-$1.54B
Cap. Flow
+$155M
Cap. Flow %
2.74%
Top 10 Hldgs %
45.45%
Holding
105
New
10
Increased
9
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
LIAN
LianBio American Depositary Shares
LIAN
+$87.4M
2
BLU
BELLUS Health Inc.
BLU
+$67.9M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$59.2M
4
RLMD icon
Relmada Therapeutics
RLMD
+$44.5M
5
XLO icon
Xilio Therapeutics
XLO
+$34.1M

Top Sells

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$190M
2
TGTX icon
TG Therapeutics
TGTX
+$49M
3
VERV
Verve Therapeutics
VERV
+$23.9M
4
CTMX icon
CytomX Therapeutics
CTMX
+$17.8M
5
WHWK
Whitehawk Therapeutics
WHWK
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.05%
2 Financials 0.78%
3 Miscellaneous 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
51
Dyne Therapeutics
DYN
$3.34B
$33.4M 0.59%
2,805,045
– –
XLO icon
52
Xilio Therapeutics
XLO
$59.4M
$32M 0.56%
+143,016
New +$34.1M
STSA
53
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$26.6M 0.47%
5,914,252
– –
KALV
54
DELISTED
KalVista Pharmaceuticals
KALV
$25.5M 0.45%
1,930,322
– –
ACHL
55
DELISTED
Achilles Therapeutics
ACHL
$25.1M 0.44%
5,014,687
– –
PYXS icon
56
Pyxis Oncology
PYXS
$278M
$25M 0.44%
+2,282,173
New +$26.1M
TNGX icon
57
Tango Therapeutics
TNGX
$4.03B
$24.6M 0.43%
2,250,000
– –
WVE icon
58
Wave Life Sciences
WVE
$879M
$24.4M 0.43%
7,775,207
– –
SLDB icon
59
Solid Biosciences
SLDB
$897M
$21.6M 0.38%
824,525
– –
OLMA icon
60
Olema Pharmaceuticals
OLMA
$856M
$20.1M 0.35%
2,150,404
– –
AKUS
61
DELISTED
Akouos Inc
AKUS
$19.4M 0.34%
2,281,249
– –
RLAY icon
62
Relay Therapeutics
RLAY
$4.16B
$16.9M 0.3%
+549,055
New +$17.4M
KDNY
63
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$16.3M 0.29%
+1,000,000
New +$14.2M
SYBX
64
DELISTED
Synlogic
SYBX
$16.1M 0.28%
444,444
– –
MIST icon
65
Milestone Pharmaceuticals
MIST
$115M
$14.7M 0.26%
2,246,503
– –
DALS
66
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$14.7M 0.26%
1,500,000
– –
IPSC icon
67
Century Therapeutics
IPSC
$359M
$14.5M 0.26%
914,094
– –
LRMR icon
68
Larimar Therapeutics
LRMR
$406M
$14.4M 0.25%
1,334,610
-180,541
-12% -$2.01M
BDTX icon
69
Black Diamond Therapeutics
BDTX
$113M
$13.8M 0.24%
2,589,904
– –
SCPH
70
DELISTED
scPharmaceuticals
SCPH
$13.5M 0.24%
2,691,770
-39,400
-1% -$217K
KALA icon
71
KALA BIO
KALA
$9.82M
$13.2M 0.23%
4,354
– –
ORTX
72
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$12.8M 0.23%
969,479
-133,393
-12% -$2.21M
NAUT icon
73
Nautilus Biotechnolgy
NAUT
$113M
$12.6M 0.22%
2,436,430
– –
BLSA
74
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$12.3M 0.22%
1,250,000
– –
IOBT
75
DELISTED
IO Biotech
IOBT
$11.9M 0.21%
+1,857,755
New +$17.9M
1 2
3
4 5

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, RA Capital Management held 105 positions worth $5.67B, down 21% from $7.22B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

RA Capital Management's Q4 2021 filing shows 10 new, 9 increased, 7 reduced and 8 closed positions. Its largest new stake was LianBio American Depositary Shares: 7,655,015 shares worth $47.2M. The largest sale was Atea Pharmaceuticals, an estimated $190M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Miscellaneous.

  • RA Capital Management's largest Q4 2021 buy was LianBio American Depositary Shares: 7,655,015 shares worth $47.2M.
  • RA Capital Management added most to Ascendis Pharma A/S in Q4 2021, an estimated $26.8M increase.
  • RA Capital Management's biggest Q4 2021 reduction was TG Therapeutics, cutting an estimated $49M.
  • RA Capital Management fully exited Atea Pharmaceuticals in Q4 2021, selling an estimated $190M.
  • RA Capital Management's ten largest holdings make up 45% of its $5.67B portfolio in Q4 2021.
  • RA Capital Management opened 10 new positions and closed 8 in Q4 2021.
  • RA Capital Management's portfolio value fell 21% quarter-over-quarter to $5.67B.

Based on RA Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.